

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

SAS

RRID:CVCL_1675

Type: Cell Line

Proper Citation

RRID:CVCL_1675

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1675

Proper Citation: RRID:CVCL_1675

Description: Cell line SAS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Tongue squamous cell carcinoma

Defining Citation: [PMID:9023415](#), [PMID:9178645](#), [PMID:9290701](#), [PMID:17325662](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:24627082](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:32990596](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SAS

Cross References: BTO:BTO_0003981, CLO:CLO_0051568, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1004, BioSample:SAMN03471668, BioSample:SAMN03472049, cancercellines:CVCL_1675, Cell_Model_Passport:SIDM00351, ChEMBL-Cells:ChEMBL3308781, ChEMBL-Targets:ChEMBL1075569, Cosmic:909708, Cosmic:1042300, Cosmic:1118787, Cosmic:1120705, Cosmic:1571803, Cosmic:2546833, Cosmic-CLP:909708, DepMap:ACH-002029, EGA:EGAS00001000978, FANTOM5_SSTAR:10544-107H4, GDSC:909708, GEO:GSM827230, GEO:GSM850387, GEO:GSM950309, GEO:GSM950310, GEO:GSM950311, GEO:GSM950312, GEO:GSM1670402,

IARC_TP53:23803, JCRB:JCRB0260, LINCS_LDP:LCL-1221,
PharmacoDB:SAS_1345_2019, PRIDE:PXD030304, Progenetix:CVCL_1675,
PubChem_Cell_line:CVCL_1675, RCB:RCB1974, TKG:TKG 0470, Wikidata:Q54952119

ID: CVCL_1675

Record Creation Time: 20220427T221516+0000

Record Last Update: 20260905T182252+0000

Ratings and Alerts

No rating or validation information has been found for SAS.

No alerts have been found for SAS.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang CW, et al. (2026) ENOX2 (tNOX)-Associated Stemness in Oral Cancer Cells and Its Clinical Correlation in Head and Neck Tumors. Antioxidants (Basel, Switzerland), 15(1).

Chen TJ, et al. (2026) GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e19368.

Jiang H, et al. (2026) Stiffness-related stress granules promote the metastasis of early-stage oral squamous cell carcinoma via anoikis resistance. Cellular oncology (Dordrecht, Netherlands), 49(3).

Watanabe A, et al. (2025) UBE2T promotes epithelial-mesenchymal transition and motility in oral cancer cells via induction of IL-6 expression. Oncology letters, 30(4), 473.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. Cell reports. Medicine, 6(11), 102448.

Peng HY, et al. (2025) EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. Neoplasia (New York, N.Y.), 66, 101193.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. Molecular cancer therapeutics, 24(4), 550.

Ozaki K, et al. (2025) Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. *The Prostate*, 85(13), 1208.

Huang YH, et al. (2025) Tribbles pseudokinase 3 drives cancer stemness in oral squamous cell carcinoma cells by supporting the expression levels of SOX2 and EGFR. *International journal of molecular medicine*, 55(3).

Schott A, et al. (2025) The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. *NAR cancer*, 7(1), zcaf006.

Lin MC, et al. (2024) Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. *Molecular oncology*, 18(2), 350.

Bizzoca ME, et al. (2024) Methods for Overcoming Chemoresistance in Head and Neck Squamous Cell Carcinoma: Keeping the Focus on Cancer Stem Cells, a Systematic Review. *Cancers*, 16(17).

Liao TT, et al. (2024) Hypoxia-Induced Long Noncoding RNA HIF1A-AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer. *Cancer immunology research*, 12(10), 1468.

Cai L, et al. (2024) Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinoma. *NPJ biofilms and microbiomes*, 10(1), 39.

Chai AWY, et al. (2024) High TNF and NF- κ B Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis. *Cancer research communications*, 4(11), 2919.

Chang HC, et al. (2024) Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer. *Heliyon*, 10(6), e28406.

Zwick A, et al. (2024) Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells. *Journal of immunology (Baltimore, Md. : 1950)*, 213(2), 148.

Chen HH, et al. (2024) DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1. *Cell reports*, 43(3), 113937.

Schniewind I, et al. (2024) Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer. *Cancers*, 16(4).

Hazawa M, et al. (2023) Super-enhancer trapping by the nuclear pore via intrinsically disordered regions of proteins in squamous cell carcinoma cells. *Cell chemical biology*.